This work was financially supported by the research program at the Centre for Addiction and Mental Health (CAMH). Support to the centre for salary of scientists and for infrastructure has been provided by the Ontario Ministry of Health and Long-Term Care. The views expressed do not necessarily reflect those of the ministry.
Dr. Mulsant is a member of the board of directors of the CAMH Foundation. He receives research support from Bristol-Myers Squibb and Pfizer (medications for a clinical trial funded by the National Institutes of Health). He owns stock in General Electric and has received some travel support from Roche. The other authors report no competing interests.